JAK inhibitors as therapy for myelofibrosis

Srdan Verstovsek; Kate J. Newberry

doi:10.2217/fmeb2014.14.14

JAK inhibitors as therapy for myelofibrosis

Srdan Verstovsek, Kate J. Newberry

Leukemia

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Myelofibrosis (MF) is a clonal myeloproliferative disorder characterized by extramedullary hematopoiesis, progressive anemia, bone marrow fibrosis and osteosclerosis, with average survival duration of 5 years.

Original language	English (US)
Title of host publication	Novel Insights into Myelofibrosis Pathophysiology and Treatment
Publisher	Future Medicine Ltd.
Pages	104-122
Number of pages	19
ISBN (Electronic)	9781780845494
ISBN (Print)	9781780845517
DOIs	https://doi.org/10.2217/fmeb2014.14.14
State	Published - May 1 2015

ASJC Scopus subject areas

General Medicine

Access to Document

10.2217/fmeb2014.14.14

Cite this

@inbook{d003b58c88b94a1198f3726cd15d8f43,

title = "JAK inhibitors as therapy for myelofibrosis",

abstract = "Myelofibrosis (MF) is a clonal myeloproliferative disorder characterized by extramedullary hematopoiesis, progressive anemia, bone marrow fibrosis and osteosclerosis, with average survival duration of 5 years.",

author = "Srdan Verstovsek and Newberry, {Kate J.}",

year = "2015",

month = may,

day = "1",

doi = "10.2217/fmeb2014.14.14",

language = "English (US)",

isbn = "9781780845517",

pages = "104--122",

booktitle = "Novel Insights into Myelofibrosis Pathophysiology and Treatment",

publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - JAK inhibitors as therapy for myelofibrosis

AU - Verstovsek, Srdan

AU - Newberry, Kate J.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Myelofibrosis (MF) is a clonal myeloproliferative disorder characterized by extramedullary hematopoiesis, progressive anemia, bone marrow fibrosis and osteosclerosis, with average survival duration of 5 years.

AB - Myelofibrosis (MF) is a clonal myeloproliferative disorder characterized by extramedullary hematopoiesis, progressive anemia, bone marrow fibrosis and osteosclerosis, with average survival duration of 5 years.

UR - http://www.scopus.com/inward/record.url?scp=84957023701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957023701&partnerID=8YFLogxK

U2 - 10.2217/fmeb2014.14.14

DO - 10.2217/fmeb2014.14.14

M3 - Chapter

AN - SCOPUS:84957023701

SN - 9781780845517

SP - 104

EP - 122

BT - Novel Insights into Myelofibrosis Pathophysiology and Treatment

PB - Future Medicine Ltd.

ER -

JAK inhibitors as therapy for myelofibrosis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this